tirzepatide cardiovascular outcome trial cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says tirzepatide outcomes trial results – tirzepatide cardiovascular outcomes trial results

These data are consistent with one of two scenarios, either (1) direct peptide-stimulated inhibition of GLP-1R and Y1-R on -cells, or (2) indirect peptide-mediated insulin release leading to inhibition of glucagon release, as observed in previous studies 50,51

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)

Refunds are issued only in cases of medical disqualification by a licensed provider

Standard platform - Internal Hex 2.42mm /1-4mm Collar